MagForce - Heading in the right direction

MagForce is making progress in its strategy to drive the uptake of NanoTherm, its thermal ablation treatment approved in Europe for brain tumours (GBM). Despite the impact of COVID-19, 17 GBM patients were treated during H120. Management expects to sustain this in H220 (c 30-40 in FY20) and triple it in FY21 (c 90-120). Safety data from the US study for prostate cancer are still expected by end-2020. However, the impact of COVID-19 means launch is now expected in H221 (vs the prior Q221 forecast). Growth in European sales, driven by reimbursement and the ongoing roll-out of devices, as well as the potential launch in the US, will be key to crystallising value. We value MagForce at €260.6m or €9.4/share.

Den vollständigen Artikel lesen ...